CN105326855A - 易吸收复合夹层式螯合镁钙片 - Google Patents
易吸收复合夹层式螯合镁钙片 Download PDFInfo
- Publication number
- CN105326855A CN105326855A CN201510705828.1A CN201510705828A CN105326855A CN 105326855 A CN105326855 A CN 105326855A CN 201510705828 A CN201510705828 A CN 201510705828A CN 105326855 A CN105326855 A CN 105326855A
- Authority
- CN
- China
- Prior art keywords
- magnesium
- calcium
- threonate
- inner core
- intermediate layer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ZFXVRMSLJDYJCH-UHFFFAOYSA-N calcium magnesium Chemical compound [Mg].[Ca] ZFXVRMSLJDYJCH-UHFFFAOYSA-N 0.000 title claims abstract description 27
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000011229 interlayer Substances 0.000 title abstract 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 48
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 24
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000011575 calcium Substances 0.000 claims abstract description 22
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 22
- JPIJQSOTBSSVTP-STHAYSLISA-N L-threonic acid Chemical compound OC[C@H](O)[C@@H](O)C(O)=O JPIJQSOTBSSVTP-STHAYSLISA-N 0.000 claims abstract description 10
- 229960002718 selenomethionine Drugs 0.000 claims abstract description 10
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 9
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims abstract description 9
- 235000005282 vitamin D3 Nutrition 0.000 claims abstract description 9
- 239000011647 vitamin D3 Substances 0.000 claims abstract description 9
- 229940021056 vitamin d3 Drugs 0.000 claims abstract description 9
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 claims abstract description 6
- 238000010521 absorption reaction Methods 0.000 claims description 24
- 229940047608 chelated magnesium Drugs 0.000 claims description 21
- 239000002131 composite material Substances 0.000 claims description 21
- 229940056902 l- threonic acid Drugs 0.000 claims description 9
- 239000004337 magnesium citrate Substances 0.000 claims description 9
- 229960005336 magnesium citrate Drugs 0.000 claims description 9
- 235000002538 magnesium citrate Nutrition 0.000 claims description 9
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims description 9
- 239000011248 coating agent Substances 0.000 claims description 8
- 238000000576 coating method Methods 0.000 claims description 8
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 8
- 229940088594 vitamin Drugs 0.000 claims description 8
- 229930003231 vitamin Natural products 0.000 claims description 8
- 235000013343 vitamin Nutrition 0.000 claims description 8
- 239000011782 vitamin Substances 0.000 claims description 8
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 8
- ZJXGOFZGZFVRHK-BALCVSAKSA-L calcium;(2r,3s)-2,3,4-trihydroxybutanoate Chemical compound [Ca+2].OC[C@H](O)[C@@H](O)C([O-])=O.OC[C@H](O)[C@@H](O)C([O-])=O ZJXGOFZGZFVRHK-BALCVSAKSA-L 0.000 abstract description 5
- 229940056905 magnesium l-threonate Drugs 0.000 abstract description 4
- YVJOHOWNFPQSPP-BALCVSAKSA-L magnesium;(2r,3s)-2,3,4-trihydroxybutanoate Chemical compound [Mg+2].OC[C@H](O)[C@@H](O)C([O-])=O.OC[C@H](O)[C@@H](O)C([O-])=O YVJOHOWNFPQSPP-BALCVSAKSA-L 0.000 abstract description 4
- 159000000007 calcium salts Chemical class 0.000 abstract description 3
- 239000013522 chelant Substances 0.000 abstract description 3
- 210000004211 gastric acid Anatomy 0.000 abstract description 3
- 159000000003 magnesium salts Chemical class 0.000 abstract description 2
- 239000010410 layer Substances 0.000 abstract 3
- 210000002784 stomach Anatomy 0.000 abstract 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 30
- 229940091250 magnesium supplement Drugs 0.000 description 30
- 239000011777 magnesium Substances 0.000 description 29
- 229910052749 magnesium Inorganic materials 0.000 description 29
- 229960005069 calcium Drugs 0.000 description 18
- 229960003563 calcium carbonate Drugs 0.000 description 18
- 235000010216 calcium carbonate Nutrition 0.000 description 18
- 230000009102 absorption Effects 0.000 description 17
- 210000000988 bone and bone Anatomy 0.000 description 14
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 9
- 229910001425 magnesium ion Inorganic materials 0.000 description 9
- 230000003203 everyday effect Effects 0.000 description 7
- 239000000395 magnesium oxide Substances 0.000 description 7
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 7
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 7
- 208000001132 Osteoporosis Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000001009 osteoporotic effect Effects 0.000 description 6
- 230000000576 supplementary effect Effects 0.000 description 6
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 5
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 5
- 239000001095 magnesium carbonate Substances 0.000 description 5
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 5
- 239000011669 selenium Substances 0.000 description 5
- 229910052711 selenium Inorganic materials 0.000 description 5
- 239000000470 constituent Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- JPIJQSOTBSSVTP-GBXIJSLDSA-N D-threonic acid Chemical compound OC[C@@H](O)[C@H](O)C(O)=O JPIJQSOTBSSVTP-GBXIJSLDSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 229940091258 selenium supplement Drugs 0.000 description 2
- PLWABIUNYVSNIB-RZVRUWJTSA-N (2s)-2-azanyl-4-methylselanyl-butanoic acid Chemical compound C[Se]CC[C@H](N)C(O)=O.C[Se]CC[C@H](N)C(O)=O PLWABIUNYVSNIB-RZVRUWJTSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- -1 Citrate anions Chemical class 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000844519 Homo sapiens Transient receptor potential cation channel subfamily M member 6 Proteins 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000011195 Profilin Human genes 0.000 description 1
- 108050001408 Profilin Proteins 0.000 description 1
- 102000003608 TRPM6 Human genes 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- DTYCRHCCLVCUDT-UHFFFAOYSA-J calcium;magnesium;tetrachloride Chemical compound [Mg+2].[Cl-].[Cl-].[Cl-].[Cl-].[Ca+2] DTYCRHCCLVCUDT-UHFFFAOYSA-J 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000035597 cooling sensation Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229960001708 magnesium carbonate Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 230000004072 osteoblast differentiation Effects 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000008060 renal absorption Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
Abstract
本发明公开了一种易吸收复合夹层式螯合镁钙片,包括内芯和外层,外层包覆在内芯外,所述的内芯包含L-苏糖酸镁、L-苏糖酸钙、维生素D3、L-硒代蛋氨酸,外层为碳酸钙,碳酸钙微溶于水,而L-苏糖酸镁、L-苏糖酸钙易溶于水,将微溶于水的碳酸钙包覆在易溶于水的L-苏糖酸镁、L-苏糖酸钙外,便于服用,外层碳酸钙在胃内经胃酸分解,释放其内的L-苏糖酸镁、L-苏糖酸钙、维生素D3、L-硒代蛋氨酸。本镁钙片内的钙盐和镁盐为螯合物形式,更易为人体吸收。
Description
技术领域
本发明涉及一种保健食品,特别涉及一种镁钙片。
背景技术
组成人体骨骼的微量矿物元素按含量占比分别为钙-镁-锌-铁-锶,其中人体内50%-60%的镁储存在骨组织中,其余的40%分布在肌肉软组织及血液体液当中。随着年龄的增加,人体骨骼中的钙和镁都在不断下降,大量研究表明骨镁的缺乏与骨质疏松的发生有着直接的联系。
骨质疏松临床表现为成骨下降、破骨增强,皮质骨变薄而松质骨空隙扩大,整体骨组织骨量下降,骨密度降低。由于破骨活动增强,导致骨矿化物钙元素的流失,所以传统的预防骨质疏松的营养学手段便是补充钙剂和促进钙在骨组织沉积的维生素D3等活性物质。
流行病学数据发现中老年人,尤其是妇女血液红细胞镁含量下降往往伴随着骨质疏松、高血压以及神经功能障碍等症状。而以往的动物实验也证明镁离子在改善神经记忆功能和促进血管舒张方面的显著作用。大量的实验数据表明人体镁元素的缺乏与骨质疏松、高血压的发生、神经肌肉功能的下降有直接的联系。
据2000年山东大学调查报告,我国居民日常食物镁元素的摄入量普遍不足300mg。而美国国家营养学会1999年给出的标准,健康成年人体每日镁元素需求量为300-400mg。人体镁元素的获取主要通过食物镁在肠道吸收和肾脏重吸收。对于中老年人群,由于食物摄入及肠道功能下降更容易导致体内镁元素的缺乏。动物实验发现,去卵巢小鼠随着体内雌激素含量的下降,结肠、直肠和肾远曲小管上升部上皮细胞膜的镁离子通道TRPM6的合成会被一种雌激素敏感蛋白REA(全称:雌激素受体活性抑制蛋白)抑制,从而导致肠道内镁离子吸收的障碍。这很可能是绝经后妇女体内镁含量降低以及更易发生骨质疏松的原因。中老年人群镁元素与钙元素的缺乏共同导致骨质疏松的发生。所以易于发生骨质疏松的人群只补钙而忽视补镁的观念是需要改变的。
因为国内大众普遍缺乏对镁元素补充的认识和重视,预防骨质疏松营养品基本都是以钙元素为主,没有或含有少量镁元素为补充成分。而且现有钙片中镁元素成分的加入只是作为宣称促进钙元素吸收。至于镁离子在消化道促进钙离子的吸收并没有科学依据。而且市场上现有的补钙制剂绝大多数以碳酸钙为主要成分,少量碳酸镁(镁元素含量10-50mg/片)为补充。至2015年九月底在国家药监局注册的补钙类营养片共32种,所有这32种营养补充剂均为碳酸盐成分。食用级碳酸钙和碳酸镁原料成本极低,利于市场推广。但是以碳酸盐为主要成分的钙镁盐类口服后必须在胃内经胃酸分解为二氧化碳和氯化钙镁盐,然后在小肠(主要在空回肠)被吸收。这样的吸收首先是不完全的,因为碳酸盐在胃内不一定全部分解,即使分解后的氯化钙和氯化镁在小肠内的碱性环境下会继续与草酸根结合形成不易溶解的草酸盐。再加上现有的钙镁片侧重于补充钙盐,镁元素的含量比较低,起不到补充健康人体镁量的需要。
发明内容
本发明为了解决现有营养片设计中镁、钙不易被人体吸收造成不足及骨质疏松的问题,而提供一种易吸收复合夹层式螯合镁钙片,将镁钙片制成夹层结构,内芯的钙盐和镁盐为螯合物形式,更易为人体吸收。
为达到上述目的,本发明采用的技术方案为:
一种易吸收复合夹层式螯合镁钙片,包括内芯和外层,外层包覆在内芯外,所述的内芯包含L-苏糖酸镁(Magnesium-L-threonate)、L-苏糖酸钙(Calcium-L-threonate)、维生素D3、L-硒代蛋氨酸(L-(+)-Selenomethionine),外层为碳酸钙。L-苏糖酸镁、L-苏糖酸钙易吸水,为避免L-苏糖酸镁、L-苏糖酸钙直接与外界接触,发生可能的吸潮现象,将微溶于水的碳酸钙(Calciumcarbonate)包覆在易溶于水的内芯外,更易保存、携带,稳定性能,外层碳酸钙在胃内经胃酸分解后,释放其内的L-苏糖酸镁、L-苏糖酸钙、维生素D3、L-硒代蛋氨酸,从而被人体吸收。
近年来对骨组织元素分析和骨质疏松机理的研究发现镁离子(在骨组织中含量远低于钙,但对骨组织一型胶原纤维矿化过程和成熟程度起关键作用)对骨内间充质干细胞向成骨细胞分化以及成骨细胞的成骨活性起显著的促进作用,同时镁离子对破骨细胞有明显的抑制作用。因此,本产品在补钙的同时添加了一定量的镁。
相比碳酸镁和碳酸钙,L-苏糖酸钙(分子量310)和L-苏糖酸镁(分子量295)都是易溶于水的螯合物,L-苏糖酸镁不仅比碳酸镁、氧化镁、柠檬酸镁更易吸收,而且还能显著提高脑脊液中的镁离子含量,从而改善动物的记忆和学习能力。L-苏糖酸钙不仅很容易为人体吸收,而且苏糖酸和L-苏糖酸钙与阿伦佐磷酸盐、雌二醇、葡萄糖酸钙相比,能够显著抑制破骨细胞活动导致的骨吸收。
柠檬酸镁(分子量215)作为镁离子的柠檬酸螯合物,比碳酸镁也更容易为人体吸收。每单位分子的柠檬酸镁含有比L-苏糖酸镁更多的镁量,同时柠檬酸阴离子和镁离子同时具有稳定非骨组织部位如血管、肾脏内钙离子聚集矿化的作用,所以柠檬酸镁对尿路结石和动脉粥样硬化也有一定缓解作用。
另外硒作为人体重要的抗氧化剂,与维生素C和维生素E联合作用下有利于防止骨质疏松骨的结构退行性改变,L-硒代蛋氨酸是易为人体吸收的硒元素的补充剂。最后,维生素D3也是促进骨组织生成的人体必需物质。本产品能够一次性补充人体缺乏的镁、钙、硒及维生素,通过四种元素在吸收及功能方面的相辅相成,能够满足人体对镁、钙、硒及维生素的需求,配方设计科学、合理、安全,尤其适用于中来年人。
作为本发明所述的易吸收复合夹层式螯合镁钙片的一种优选方案,所述的外层外侧还设有包衣,具有服用、保存、外出携带都很方便的优点,包衣由薄荷脑组成,薄荷脑可以改善镁钙片的口感,给人以清凉感觉,使人们更喜欢服用。
作为本发明所述的易吸收复合夹层式螯合镁钙片的一种优选方案,所述的外层还含有薄荷脑,不需要额外的包衣,直接在外层的碳酸钙内混合薄荷脑,工艺更加简洁,同时能达到改善口感的效果。
作为本发明所述的易吸收复合夹层式螯合镁钙片的一种优选方案,所述的内芯包含590-1770mgL-苏糖酸镁、310-2170mgL-苏糖酸钙、2.0-3.5μg维生素D3、60-120μgL-硒代蛋氨酸,进一步地,所述的内芯包含590-1770mgL-苏糖酸镁、310-2170mgL-苏糖酸钙、2.5μg维生素D3、100μgL-硒代蛋氨酸。
作为本发明所述的易吸收复合夹层式螯合镁钙片的一种优选方案,所述的内芯还含有柠檬酸镁。
作为本发明所述的易吸收复合夹层式螯合镁钙片的一种优选方案,所述的内芯包含590-1770mgL-苏糖酸镁、50-450mg柠檬酸镁、310-2170mgL-苏糖酸钙、2.0-3.5μg维生素D3、60-120μgL-硒代蛋氨酸。
作为本发明所述的易吸收复合夹层式螯合镁钙片的一种优选方案,所述的外层为50-200mg碳酸钙。
附图说明
图1是一种易吸收复合夹层式螯合镁钙片结构示意图。
图2为另一种易吸收复合夹层式螯合镁钙片结构示意图。
其中:1、内芯2、外层3、包衣
具体实施方式
下面结合附图和具体实施方式对本发明作进一步详细说明。
实施例
如图1所示,一种易吸收复合夹层式螯合镁钙片,由内到外依次为内芯1、外层2,内芯包含L-苏糖酸镁、L-苏糖酸钙、维生素D3、L-硒代蛋氨酸,外层为碳酸钙。进一步的,在内芯内可以添加一定量的柠檬酸镁,对尿路结石和动脉粥样硬化也有一定缓解作用。
其中,一片镁钙片中各成分的可以按照下表进行配置,按照美国国家营养协会1999年健康人体微量元素摄入标准:我们把每片片剂内所含的镁元素的量定位50-100mg,按每天服用2-3片的指导摄入量,每天可额外补充将近100-300mg的镁。考虑到我国居民日常摄入的镁量通常不足300mg,而推荐每日镁的摄入量为300-400mg,我们设计的新型镁片可以满足成年人,中老年人每日基本的镁需求量(每天2-3片)。如果是处于绝经后期的妇女,以及肠功能吸收障碍的老年人可能对食物中的镁不能充分吸收,那便需要增加服用量。而片剂中的钙含量在每片200mg左右,即使服用4片也不会超过每天2500mg的人体耐受上限。另外硒和维生素D3的含量也在人体耐受量之内。
镁钙片中各主要成分配比表
为了改进镁钙片的口感,可以在外层的碳酸钙内添加适量的薄荷脑。
如图2所示,一种易吸收复合夹层式螯合镁钙片,由内到外依次为内芯1、外层2、包衣3,外层为碳酸钙,包衣内添加薄荷脑,用来改善口感,更加便于携带和储存。
虽然说明书中对本发明的实施方式进行了说明,但这些实施方式只是作为提示,不应限定本发明的保护范围。在不脱离本发明宗旨的范围内进行各种省略、置换和变更均应包含在本发明的保护范围内。
Claims (8)
1.一种易吸收复合夹层式螯合镁钙片,其特征在于:包括内芯和外层,外层包覆在内芯外,所述的内芯包含L-苏糖酸镁、L-苏糖酸钙、维生素D3、L-硒代蛋氨酸,外层主要成分为碳酸钙。
2.根据权利要求1所述的易吸收复合夹层式螯合镁钙片,其特征在于:在外层外侧还设有包衣,包衣由薄荷脑组成。
3.根据权利要求1所述的易吸收复合夹层式螯合镁钙片,其特征在于:所述的外层还含有薄荷脑。
4.根据权利要求1到3任意一项所述的易吸收复合夹层式螯合镁钙片,其特征在于:所述的内芯包含590-1770mgL-苏糖酸镁、310-2170mgL-苏糖酸钙、2.0-3.5μg维生素D3、60-120μgL-硒代蛋氨酸。
5.根据权利要求1到3任意一项所述的易吸收复合夹层式螯合镁钙片,其特征在于:所述的内芯包含590-1770mgL-苏糖酸镁、310-2170mgL-苏糖酸钙、2.5μg维生素D3、100μgL-硒代蛋氨酸。
6.根据权利要求1到3任意一项所述的易吸收复合夹层式螯合镁钙片,其特征在于:所述的内芯还含有柠檬酸镁。
7.根据权利要求6所述的易吸收复合夹层式螯合镁钙片,其特征在于:所述的内芯包含590-1770mgL-苏糖酸镁、50-450mg柠檬酸镁、310-2170mgL-苏糖酸钙、2.0-3.5μg维生素D3、60-120μgL-硒代蛋氨酸。
8.根据权利要求4所述的易吸收复合夹层式螯合镁钙片,其特征在于:所述的外层为50-200mg碳酸钙。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510705828.1A CN105326855A (zh) | 2015-10-27 | 2015-10-27 | 易吸收复合夹层式螯合镁钙片 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510705828.1A CN105326855A (zh) | 2015-10-27 | 2015-10-27 | 易吸收复合夹层式螯合镁钙片 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105326855A true CN105326855A (zh) | 2016-02-17 |
Family
ID=55277761
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510705828.1A Pending CN105326855A (zh) | 2015-10-27 | 2015-10-27 | 易吸收复合夹层式螯合镁钙片 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105326855A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112384210A (zh) * | 2018-04-25 | 2021-02-19 | 纽罗森特里亚股份有限公司 | 苏糖酸镁组合物及其用途 |
CN113854571A (zh) * | 2021-09-29 | 2021-12-31 | 山东大学齐鲁医院 | 硒制剂在制备股骨头坏死性疾病保健食品、药物中的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1200366A (zh) * | 1997-08-29 | 1998-12-02 | 北京巨能亚太生命科学研究中心 | 新l-苏糖酸衍生物 |
CN1566086A (zh) * | 2003-06-18 | 2005-01-19 | 吴琼 | 一种氨基酸螯合钙及其制剂和应用 |
CN104114500A (zh) * | 2011-12-13 | 2014-10-22 | 曼普雷特·S·沃德瓦 | 液体膳食补充品制剂组合物 |
-
2015
- 2015-10-27 CN CN201510705828.1A patent/CN105326855A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1200366A (zh) * | 1997-08-29 | 1998-12-02 | 北京巨能亚太生命科学研究中心 | 新l-苏糖酸衍生物 |
CN1566086A (zh) * | 2003-06-18 | 2005-01-19 | 吴琼 | 一种氨基酸螯合钙及其制剂和应用 |
CN104114500A (zh) * | 2011-12-13 | 2014-10-22 | 曼普雷特·S·沃德瓦 | 液体膳食补充品制剂组合物 |
Non-Patent Citations (1)
Title |
---|
无: ""活力钙镁片"", 《互动百科,HTTP://WWW.BAIKE.COM/WIKI/%E6%B4%BB%E5%8A%9B%E9%92%99%E9%95%81%E7%89%87》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112384210A (zh) * | 2018-04-25 | 2021-02-19 | 纽罗森特里亚股份有限公司 | 苏糖酸镁组合物及其用途 |
US11717501B2 (en) | 2018-04-25 | 2023-08-08 | Neurocentria, Inc. | Magnesium threonate compositions and uses thereof |
CN113854571A (zh) * | 2021-09-29 | 2021-12-31 | 山东大学齐鲁医院 | 硒制剂在制备股骨头坏死性疾病保健食品、药物中的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20110128329A (ko) | 인산염 흡착제 | |
CN102415447B (zh) | 一种适用于婴幼儿的补钙冲剂及其制备工艺 | |
CN101850002A (zh) | 一种具有改善营养性贫血功能的组合物 | |
Huo et al. | Preparation and biological efficacy of haddock bone calcium tablets | |
CN105326855A (zh) | 易吸收复合夹层式螯合镁钙片 | |
KR101171068B1 (ko) | 미네랄 조성물을 유효 성분으로 함유하는 당뇨 개선 및 예방용 약학적 조성물 | |
CN105288579A (zh) | 一种补钙制剂及其制备方法 | |
CN102727865A (zh) | 一种不含碳酸钙与维生素d的复合钙胶囊 | |
JP2003246738A (ja) | マグネシウム強化液並びにそれを用いた保湿剤、化粧品及び飲料 | |
Clarkson et al. | Evaluation of the solubility of a range of copper sources and the effects of iron & sulphur on copper solubility under rumen simulated conditions | |
JP2008237058A (ja) | 栄養補助食品 | |
CA3069811A1 (en) | Blood flow improver | |
CN108851037A (zh) | 一种肾病综合征全营养食品的制备方法及其用途 | |
Gulaboglu et al. | Urine and saliva iodine levels in patients with dental caries and normal healthy volunteers. | |
CN102342400A (zh) | 高钙木糖醇 | |
Merrell | The importance of minerals in the long term health of humans | |
CN102626420B (zh) | 一种含有锶、钙和维生素d的混合制剂 | |
CN103445171A (zh) | 血液酸碱平衡剂 | |
RU2342937C1 (ru) | Состав для промывания носовой полости, носоглотки и полости рта | |
TW460285B (en) | A process for preparing calcium containing composition with high oral bioavailability | |
CN107595829B (zh) | 一种防治肾性骨营养不良的组合物 | |
CN103734436A (zh) | 一种补充矿物质型牦牛乳蛋白质糖及其制备方法 | |
RU2274453C1 (ru) | Фармацевтическая композиция для стабилизации гемостаза и купирования патологических процессов в организме | |
CN102187992A (zh) | 一种平衡含碘盐及加工方法 | |
CN107753716A (zh) | 一种基于多靶点干预治疗慢性荨麻疹的活性组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160217 |